A Phase IIb Study to Determine the Efficacy and Safety of the Study Drug in Patients With Severe Sepsis
NCT ID: NCT00034476
Last Updated: 2006-07-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1/PHASE2
466 participants
INTERVENTIONAL
2001-10-31
2002-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The study drug is an investigational drug that is still in development. It has been studied in approximately 30 healthy subjects, approximately 30 patients with either kidney failure or arthritis, and approximately 600 patients with severe sepsis. Patient participation in this study will last for about one month.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
sPLA2 Inhibitor
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* meet specified time windows
* be 18 years of age or older
Exclusion Criteria
* have undergone certain organ transplants
* be HIV positive
* be pregnant or breast feeding
* have severe underlying medical problems
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eli Lilly and Company
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Birmingham, Alabama, United States
Phoenix, Arizona, United States
Berkeley, California, United States
Los Angeles, California, United States
Orange, California, United States
San Diego, California, United States
Torrance, California, United States
Denver, Colorado, United States
Washington D.C., District of Columbia, United States
Brandon, Florida, United States
Clearwater, Florida, United States
Lakeland, Florida, United States
Miami, Florida, United States
Orlando, Florida, United States
Tampa, Florida, United States
Augusta, Georgia, United States
Chicago, Illinois, United States
Oak Park, Illinois, United States
Springfield, Illinois, United States
Indianapolis, Indiana, United States
Des Moines, Iowa, United States
Iowa City, Iowa, United States
Kansas City, Kansas, United States
Lexington, Kentucky, United States
Lake Charles, Louisiana, United States
New Orleans, Louisiana, United States
Shreveport, Louisiana, United States
Portland, Maine, United States
Baltimore, Maryland, United States
Boston, Massachusetts, United States
Springfield, Massachusetts, United States
Ann Arbor, Michigan, United States
Detroit, Michigan, United States
Minneapolis, Minnesota, United States
Saint Lous, Missouri, United States
Reno, Nevada, United States
East Orange, New Jersey, United States
New Brunswick, New Jersey, United States
Great Neck, New York, United States
Manhasset, New York, United States
New Hyde Park, New York, United States
New York, New York, United States
The Bronx, New York, United States
Chapel Hill, North Carolina, United States
Greensboro, North Carolina, United States
Winston-Salem, North Carolina, United States
Akron, Ohio, United States
Toledo, Ohio, United States
Portland, Oregon, United States
Hershey, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
Pittsburgh, Pennsylvania, United States
Providence, Rhode Island, United States
Memphis, Tennessee, United States
Houston, Texas, United States
San Antonio, Texas, United States
Falls Church, Virginia, United States
Seattle, Washington, United States
Madison, Wisconsin, United States
Milwaukee, Wisconsin, United States
Brussels, , Belgium
Ghent, , Belgium
Liège, , Belgium
Ottignies, , Belgium
Yvior, , Belgium
Budapest, , Hungary
Debrecen, , Hungary
Debrecend, , Hungary
Miskolc, , Hungary
Pécs, , Hungary
Szeged, , Hungary
Vác, , Hungary
's-Hertogenbosch, , Netherlands
Apeldoorn, , Netherlands
Breda, , Netherlands
Groningen, , Netherlands
Nijmegen, , Netherlands
Rotterdam, , Netherlands
Gdansk, , Poland
Krakow-Nowa Huta, , Poland
Poznan, , Poland
Sosnowiec, , Poland
Szczecin, , Poland
Warsaw, , Poland
Wroclaw, , Poland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
J4A-MC-EZZI
Identifier Type: -
Identifier Source: secondary_id
1641
Identifier Type: -
Identifier Source: org_study_id